Interaction between multimeric von willebrand factor and complement: A fresh look to the pathophysiology of microvascular thrombosis

Serena Bettoni, Miriam Galbusera, Sara Gastoldi, Roberta Donadelli, Chiara Tentori, Giuseppina Spartà, Elena Bresin, Caterina Mele, Marta Alberti, Agustin Tortajada, Hugo Yebenes, Giuseppe Remuzzi, Marina Noris

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

vonWillebrand factor (VWF), a multimeric protein with a central role in hemostasis, has been shown to interact with complement components. However, results are contrasting and inconclusive. By studying 20 patients with congenital thrombotic thrombocytopenic purpura (cTTP) who cannot cleave VWF multimers because of genetic ADAMTS13 deficiency, we investigated the mechanism through which VWF modulates complement and its pathophysiological implications for human diseases. Using assays of ex vivo serum-induced C3 and C5b-9 deposits on endothelial cells, we documented that in cTTP, complement is activated via the alternative pathway (AP) on the cell surface. This abnormality was corrected by restoring ADAMTS13 activity in cTTP serum, which prevented VWF multimer accumulation on endothelial cells, or by an anti-VWF Ab. In mechanistic studies we found that VWF interacts with C3b through its three type A domains and initiates AP activation, although assembly of active C5 convertase and formation of the terminal complement products C5a and C5b-9 occur only on the VWF-A2 domain. Finally, we documented that in the condition of ADAMTS13 deficiency, VWF-mediated formation of terminal complement products, particularly C5a, alters the endothelial antithrombogenic properties and induces microvascular thrombosis in a perfusion system. Altogether, the results demonstrated that VWF provides a platform for the activation of the AP of complement, which profoundly alters the phenotype of microvascular endothelial cells. These findings link hemostasis-thrombosis with the AP of complement and open new therapeutic perspectives in cTTP and in general in thrombotic and inflammatory disorders associated with endothelium perturbation, VWF release, and complement activation.

Original languageEnglish
Pages (from-to)1021-1040
Number of pages20
JournalJournal of Immunology
Volume199
Issue number3
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Thrombotic Thrombocytopenic Purpura
von Willebrand Factor
Thrombosis
Alternative Complement Pathway
Complement Membrane Attack Complex
Endothelial Cells
Hemostasis
Complement C5b
Complement C3-C5 Convertases
Complement C5a
Complement Activation
Serum
varespladib methyl
Endothelium
Perfusion
Phenotype
Proteins
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

Interaction between multimeric von willebrand factor and complement : A fresh look to the pathophysiology of microvascular thrombosis. / Bettoni, Serena; Galbusera, Miriam; Gastoldi, Sara; Donadelli, Roberta; Tentori, Chiara; Spartà, Giuseppina; Bresin, Elena; Mele, Caterina; Alberti, Marta; Tortajada, Agustin; Yebenes, Hugo; Remuzzi, Giuseppe; Noris, Marina.

In: Journal of Immunology, Vol. 199, No. 3, 01.08.2017, p. 1021-1040.

Research output: Contribution to journalArticle

Bettoni, Serena ; Galbusera, Miriam ; Gastoldi, Sara ; Donadelli, Roberta ; Tentori, Chiara ; Spartà, Giuseppina ; Bresin, Elena ; Mele, Caterina ; Alberti, Marta ; Tortajada, Agustin ; Yebenes, Hugo ; Remuzzi, Giuseppe ; Noris, Marina. / Interaction between multimeric von willebrand factor and complement : A fresh look to the pathophysiology of microvascular thrombosis. In: Journal of Immunology. 2017 ; Vol. 199, No. 3. pp. 1021-1040.
@article{48205ef433f24c90b6e655f9f887ff2f,
title = "Interaction between multimeric von willebrand factor and complement: A fresh look to the pathophysiology of microvascular thrombosis",
abstract = "vonWillebrand factor (VWF), a multimeric protein with a central role in hemostasis, has been shown to interact with complement components. However, results are contrasting and inconclusive. By studying 20 patients with congenital thrombotic thrombocytopenic purpura (cTTP) who cannot cleave VWF multimers because of genetic ADAMTS13 deficiency, we investigated the mechanism through which VWF modulates complement and its pathophysiological implications for human diseases. Using assays of ex vivo serum-induced C3 and C5b-9 deposits on endothelial cells, we documented that in cTTP, complement is activated via the alternative pathway (AP) on the cell surface. This abnormality was corrected by restoring ADAMTS13 activity in cTTP serum, which prevented VWF multimer accumulation on endothelial cells, or by an anti-VWF Ab. In mechanistic studies we found that VWF interacts with C3b through its three type A domains and initiates AP activation, although assembly of active C5 convertase and formation of the terminal complement products C5a and C5b-9 occur only on the VWF-A2 domain. Finally, we documented that in the condition of ADAMTS13 deficiency, VWF-mediated formation of terminal complement products, particularly C5a, alters the endothelial antithrombogenic properties and induces microvascular thrombosis in a perfusion system. Altogether, the results demonstrated that VWF provides a platform for the activation of the AP of complement, which profoundly alters the phenotype of microvascular endothelial cells. These findings link hemostasis-thrombosis with the AP of complement and open new therapeutic perspectives in cTTP and in general in thrombotic and inflammatory disorders associated with endothelium perturbation, VWF release, and complement activation.",
author = "Serena Bettoni and Miriam Galbusera and Sara Gastoldi and Roberta Donadelli and Chiara Tentori and Giuseppina Spart{\`a} and Elena Bresin and Caterina Mele and Marta Alberti and Agustin Tortajada and Hugo Yebenes and Giuseppe Remuzzi and Marina Noris",
year = "2017",
month = "8",
day = "1",
doi = "10.4049/jimmunol.1601121",
language = "English",
volume = "199",
pages = "1021--1040",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "3",

}

TY - JOUR

T1 - Interaction between multimeric von willebrand factor and complement

T2 - A fresh look to the pathophysiology of microvascular thrombosis

AU - Bettoni, Serena

AU - Galbusera, Miriam

AU - Gastoldi, Sara

AU - Donadelli, Roberta

AU - Tentori, Chiara

AU - Spartà, Giuseppina

AU - Bresin, Elena

AU - Mele, Caterina

AU - Alberti, Marta

AU - Tortajada, Agustin

AU - Yebenes, Hugo

AU - Remuzzi, Giuseppe

AU - Noris, Marina

PY - 2017/8/1

Y1 - 2017/8/1

N2 - vonWillebrand factor (VWF), a multimeric protein with a central role in hemostasis, has been shown to interact with complement components. However, results are contrasting and inconclusive. By studying 20 patients with congenital thrombotic thrombocytopenic purpura (cTTP) who cannot cleave VWF multimers because of genetic ADAMTS13 deficiency, we investigated the mechanism through which VWF modulates complement and its pathophysiological implications for human diseases. Using assays of ex vivo serum-induced C3 and C5b-9 deposits on endothelial cells, we documented that in cTTP, complement is activated via the alternative pathway (AP) on the cell surface. This abnormality was corrected by restoring ADAMTS13 activity in cTTP serum, which prevented VWF multimer accumulation on endothelial cells, or by an anti-VWF Ab. In mechanistic studies we found that VWF interacts with C3b through its three type A domains and initiates AP activation, although assembly of active C5 convertase and formation of the terminal complement products C5a and C5b-9 occur only on the VWF-A2 domain. Finally, we documented that in the condition of ADAMTS13 deficiency, VWF-mediated formation of terminal complement products, particularly C5a, alters the endothelial antithrombogenic properties and induces microvascular thrombosis in a perfusion system. Altogether, the results demonstrated that VWF provides a platform for the activation of the AP of complement, which profoundly alters the phenotype of microvascular endothelial cells. These findings link hemostasis-thrombosis with the AP of complement and open new therapeutic perspectives in cTTP and in general in thrombotic and inflammatory disorders associated with endothelium perturbation, VWF release, and complement activation.

AB - vonWillebrand factor (VWF), a multimeric protein with a central role in hemostasis, has been shown to interact with complement components. However, results are contrasting and inconclusive. By studying 20 patients with congenital thrombotic thrombocytopenic purpura (cTTP) who cannot cleave VWF multimers because of genetic ADAMTS13 deficiency, we investigated the mechanism through which VWF modulates complement and its pathophysiological implications for human diseases. Using assays of ex vivo serum-induced C3 and C5b-9 deposits on endothelial cells, we documented that in cTTP, complement is activated via the alternative pathway (AP) on the cell surface. This abnormality was corrected by restoring ADAMTS13 activity in cTTP serum, which prevented VWF multimer accumulation on endothelial cells, or by an anti-VWF Ab. In mechanistic studies we found that VWF interacts with C3b through its three type A domains and initiates AP activation, although assembly of active C5 convertase and formation of the terminal complement products C5a and C5b-9 occur only on the VWF-A2 domain. Finally, we documented that in the condition of ADAMTS13 deficiency, VWF-mediated formation of terminal complement products, particularly C5a, alters the endothelial antithrombogenic properties and induces microvascular thrombosis in a perfusion system. Altogether, the results demonstrated that VWF provides a platform for the activation of the AP of complement, which profoundly alters the phenotype of microvascular endothelial cells. These findings link hemostasis-thrombosis with the AP of complement and open new therapeutic perspectives in cTTP and in general in thrombotic and inflammatory disorders associated with endothelium perturbation, VWF release, and complement activation.

UR - http://www.scopus.com/inward/record.url?scp=85026216890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026216890&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1601121

DO - 10.4049/jimmunol.1601121

M3 - Article

C2 - 28652401

AN - SCOPUS:85026216890

VL - 199

SP - 1021

EP - 1040

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 3

ER -